17-beta-hydroxysteroid dehydrogenase deficiency medical therapy: Difference between revisions
Jump to navigation
Jump to search
Jose Loyola (talk | contribs) |
|||
| Line 6: | Line 6: | ||
==Medical therapy== | ==Medical therapy== | ||
*If the diagnosis of 17 beta hydroxysteroid dehydrogenase deficiency is made at birth, [[gender]] assignment should be | *If the diagnosis of 17 beta hydroxysteroid dehydrogenase deficiency is made at birth, [[gender]] assignment should be discussed. Patients with this disorder usually develop male gender identity and many patients who are raised as girls often change to male gender identity after puberty onset. Affected Individuals who are raised as males are able to undergo male development without much medical intervention.<ref name="pmid16010463">{{cite journal| author=Cohen-Kettenis PT| title=Gender change in 46,XY persons with 5alpha-reductase-2 deficiency and 17beta-hydroxysteroid dehydrogenase-3 deficiency. | journal=Arch Sex Behav | year= 2005 | volume= 34 | issue= 4 | pages= 399-410 | pmid=16010463 | doi=10.1007/s10508-005-4339-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16010463 }} </ref><ref name="pmid2082839">{{cite journal| author=Melnik B, Hollmann J, Hofmann U, Yuh MS, Plewig G| title=Lipid composition of outer stratum corneum and nails in atopic and control subjects. | journal=Arch Dermatol Res | year= 1990 | volume= 282 | issue= 8 | pages= 549-51 | pmid=2082839 | doi=10.1007/BF00371952 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2082839 }} </ref> | ||
*Patients with 17 beta hydroxysteroid dehydrogenase deficiency have moderate risk of germ cell tumor development and close monitoring is required.<ref name="pmid2082839">{{cite journal| author=Melnik B, Hollmann J, Hofmann U, Yuh MS, Plewig G| title=Lipid composition of outer stratum corneum and nails in atopic and control subjects. | journal=Arch Dermatol Res | year= 1990 | volume= 282 | issue= 8 | pages= 549-51 | pmid=2082839 | doi=10.1007/BF00371952 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2082839 }} </ref> | *Patients with 17 beta hydroxysteroid dehydrogenase deficiency have moderate risk of germ cell tumor development and close monitoring is required.<ref name="pmid2082839">{{cite journal| author=Melnik B, Hollmann J, Hofmann U, Yuh MS, Plewig G| title=Lipid composition of outer stratum corneum and nails in atopic and control subjects. | journal=Arch Dermatol Res | year= 1990 | volume= 282 | issue= 8 | pages= 549-51 | pmid=2082839 | doi=10.1007/BF00371952 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2082839 }} </ref> | ||
*Gender identity starts to develop around age 3 but it is not clear when it can be reliably assessed. | *Gender identity starts to develop around age 3 but it is not clear when it can be reliably assessed. | ||
Revision as of 07:26, 20 October 2022
|
17-beta-hydroxysteroid dehydrogenase deficiency Microchapters |
|
Differentiating 17-beta-hydroxysteroid dehydrogenase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
17-beta-hydroxysteroid dehydrogenase deficiency medical therapy On the Web |
|
American Roentgen Ray Society Images of 17-beta-hydroxysteroid dehydrogenase deficiency medical therapy |
|
FDA on 17-beta-hydroxysteroid dehydrogenase deficiency medical therapy |
|
CDC on 17-beta-hydroxysteroid dehydrogenase deficiency medical therapy |
|
17-beta-hydroxysteroid dehydrogenase deficiency medical therapy in the news |
|
Blogs on 17-beta-hydroxysteroid dehydrogenase deficiency medical therapy |
|
Directions to Hospitals Treating 17-beta-hydroxysteroid dehydrogenase deficiency |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdulkerim Yassin, M.B.B.S[2]
Overview
If the diagnosis of 17 beta hydroxysteroid dehydrogenase deficiency is made at birth, gender assignment should be discussed, depending on the expected result of virilization genioplasty.
Medical therapy
- If the diagnosis of 17 beta hydroxysteroid dehydrogenase deficiency is made at birth, gender assignment should be discussed. Patients with this disorder usually develop male gender identity and many patients who are raised as girls often change to male gender identity after puberty onset. Affected Individuals who are raised as males are able to undergo male development without much medical intervention.[1][2]
- Patients with 17 beta hydroxysteroid dehydrogenase deficiency have moderate risk of germ cell tumor development and close monitoring is required.[2]
- Gender identity starts to develop around age 3 but it is not clear when it can be reliably assessed.
References
- ↑ Cohen-Kettenis PT (2005). "Gender change in 46,XY persons with 5alpha-reductase-2 deficiency and 17beta-hydroxysteroid dehydrogenase-3 deficiency". Arch Sex Behav. 34 (4): 399–410. doi:10.1007/s10508-005-4339-4. PMID 16010463.
- ↑ 2.0 2.1 Melnik B, Hollmann J, Hofmann U, Yuh MS, Plewig G (1990). "Lipid composition of outer stratum corneum and nails in atopic and control subjects". Arch Dermatol Res. 282 (8): 549–51. doi:10.1007/BF00371952. PMID 2082839.